Also trades as: NTRB (NASDAQ) · $vol 0M
NTRBW NASDAQ
Nutriband Inc.
1W: +13.4%
1M: +5.8%
3M: -2.3%
YTD: -21.1%
1Y: -25.3%
3Y: -38.6%
$1.27
+0.16 (+14.41%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$14.5M
52W Range0.8-4.5
Volume5,215
Avg Volume163
Beta1.93
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOGareth Sheridan
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-01
Websitenutriband.com
121 South Orange Avenue
Orlando, FL 32801
US
Orlando, FL 32801
US
407 377 6695
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Latest News
Nutriband (NASDAQ:NTRBW) Trading Down 13% – Here’s What Happened
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
Nutriband (NASDAQ:NTRBW) Shares Down 0.9% – Here’s What Happened
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sheridan Gareth | 0 | — | 2025-01-31 | |
| Sheridan Gareth | A-Award | 29,333 | $8.07 | 2025-01-29 |
| Goodman Gerald | A-Award | 17,667 | $7.34 | 2025-01-23 |
| Goodman Gerald | M-Exempt | 87,500 | $1.93 | 2024-06-06 |
| Goodman Gerald | X-InTheMoney | 60,085 | $1.93 | 2024-06-05 |